Dupilumab approved for use in eczema patients in Singapore, but treatment is costly

📆 6/30/2019 11:17 AM
📰 The Straits Times

⏱ Reading Time:
19 sec. here
2 min. at publisher
📊 Quality Score:
News: 11%
Publisher: 63%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Dupilumab approved for use in eczema patients in Singapore, but treatment is costly.

SINGAPORE - A newly approved first-of-its-kind biologic drug may bring hope to patients who are having a hard time bringing their moderate to severe atopic eczema under control.

Some patients at both public and private institutions, including adolescents, have been treated with the newly available Dupilumab, sold under the brand name Dupixent, which has been shown to be relatively safe and effective in international trials that included Singapore. The Health Sciences Authority approved its use in adult patients about two months ago.

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Keita on treatment table again in Cup of Nations blowNaby Keita's return from injury looks to have been short-lived with Guinea announcing on Friday he is unsure of competing in their must-win last ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »